Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC

to Relmada and the NDV-01 program

Phase 3 trial for NDV-01 expected to begin in H1 2026

Read more at globenewswire.com